Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for ADMA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 136.02M
March 31, 2026 138.15M
December 31, 2025 87.63M
September 30, 2025 61.38M
June 30, 2025 90.28M
March 31, 2025 71.62M
December 31, 2024 103.15M
September 30, 2024 86.71M
June 30, 2024 88.24M
March 31, 2024 45.32M
December 31, 2023 51.35M
September 30, 2023 74.16M
June 30, 2023 62.51M
March 31, 2023 69.20M
December 31, 2022 86.52M
September 30, 2022 34.91M
June 30, 2022 52.42M
March 31, 2022 69.50M
December 31, 2021 51.09M
September 30, 2021 34.41M
June 30, 2021 42.41M
March 31, 2021 61.97M
December 31, 2020 55.92M
September 30, 2020 59.68M
June 30, 2020 75.78M
Date Value
March 31, 2020 101.24M
December 31, 2019 26.75M
September 30, 2019 48.01M
June 30, 2019 73.62M
March 31, 2019 16.53M
December 31, 2018 22.75M
September 30, 2018 42.37M
June 30, 2018 55.15M
March 31, 2018 27.62M
December 31, 2017 44.61M
September 30, 2017 13.60M
June 30, 2017 25.57M
March 31, 2017 8.788M
December 31, 2016 15.31M
September 30, 2016 18.93M
June 30, 2016 23.82M
March 31, 2016 11.62M
December 31, 2015 16.81M
September 30, 2015 20.94M
June 30, 2015 23.75M
March 31, 2015 28.08M
December 31, 2014 21.85M
September 30, 2014 20.27M
June 30, 2014 24.18M
March 31, 2014 28.72M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Erasca, Inc. 268.74M
Krystal Biotech, Inc. 845.63M
Vericel Corp. 162.46M
Emergent BioSolutions, Inc. 140.90M
Exelixis, Inc. 839.38M